Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exosomal microRNAs as potential biomarkers for osimertinib resistance of non-small cell lung cancer patients

20 Apr 2021

Abstract excerpt

BACKGROUND: Osimertinib is an epidermal growth factor receptor-tyrosine kinase inhibitor that specifically targets the T790M mutation in cancer.Unfortunately, most non-small cell lung cancer (NSCLC) patients develop osimertinib resistance. Currently, the molecular biomarkers for monitoring osimertinib resistance are not available. OBJECTIVE: This study aimed to examine the profile of exosomal miRNA in the plasma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Extracellular vesicles in disease
Share to Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33896827
DOI: 10.3233/cbm-203075

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exosomal microRNAs as potential biomarkers for osimertinib resistance of non-small cell lung cancer patientsPMID 33896827Read ↗

Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancerSemantic proximity Read ↗

Elevated Exosome-derived Mirnas Predict Osimertinib Resistance in Non-small Cell Lung CancerSemantic proximity Read ↗

Exosome-derived miR-210 involved in resistance to osimertinib and epithelial-mesenchymal transition in EGFR mutant non-small cell lung cancer cells.Semantic proximity Read ↗

Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Exosomes miR-184 and miR-3913-5p are involved in Osimertinib resistance in non-small cell lung cancer patients with exon 21 L858R mutationSemantic proximity Read ↗

EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcomeSemantic proximity Read ↗

Characterization of circRNAs in established osimertinib‑resistant non‑small cell lung cancer cell linesSemantic proximity Read ↗

Lnc-TMEM132D-AS1 Confers Acquired Resistance to Osimertinib in Non-Small-Cell Lung CancerSemantic proximity Read ↗

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients.Semantic proximity Read ↗

Exosomal non-coding RNAs-mediated EGFR-TKIs resistance in NSCLC with EGFR mutation.Semantic proximity Read ↗

Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib.Semantic proximity Read ↗

MicroRNA-130a-3p regulates osimertinib resistance by targeting runt-related transcription factor 3 in lung adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.